Esperion Therapeutics, Inc. — Director's Dealing 2013

Jun 26, 2013

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2013-06-25

Reporting Person: Halak Brian K (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	21471	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (1786012)		Indirect
Warrant to Purchase Series A Preferred Stock	$1.00	2018-02-12	Series A Preferred Stock (489320)		Indirect
Series A Preferred Stock	$		Common Stock (30462)		Indirect
Warrant to Purchase Series A Preferred Stock	$1.00	2018-02-12	Series A Preferred Stock (8346)		Indirect

Footnotes

F1: All outstanding shares of the Issuer's preferred stock will automatically convert into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration.

F2: The Warrant is immediately exercisable.

F3: Upon the closing of the IPO the Warrants to purchase Series A Preferred Stock will automatically convert on a 6.986-for-1 basis into Warrarts to purchase Common Stock, and the exercise price will adjust to $6.99 per share, pursuant to the terms of such Warrants.

F4: The Reporting Person is a Managing Member of (i) One Palmer Square Associates VII, LLC, which is the sole general partner of Domain Partners VII, L.P. and DP VII Associates, L.P., and (ii) Domain Associates, LLC. Pursuant to Instruction (5)(b)(iv) of Form 3, the Reporting Person has elected to report as indirectly beneficially owned the entire number of securities beneficially owned by each such entity. The Reporting Person disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.